Table 2.

Treatment courses and outcomes of rituximab therapy for idiopathic MN

ReferenceRituximab Treatment DoseConcomitant TherapyFollow-Up PeriodComplete Remission (definition per study, otherwise proteinuria ≤0.3 g/24h)Partial Remission (definition per study, otherwise ≥50% reduction in proteinuria with proteinuria <3.5 g/24h)Mean Percent Reduction in Proteinuria
Remuzzi et al. (2002)375 mg/m2 once weekly × 4Full dose ACE-I20 wk2/8 (proteinuria ≤1 g/24h)3/8 (proteinuria >1 g/24h and ≤3.5 g/24h)−57%
Ruggenenti et al. (2003)a375 mg/m2 once weekly × 4Full dose ACE-I12 mo2/8 (proteinuria ≤1g /24h)3/8 (proteinuria >1 g/24h and ≤3.5 g/24h)−65%
Rossi et al. (2005)375 mg/m2 once weekly × 4, then 375 mg/m2 once monthly × 5Methylprednisolone, slowly tapered and discontinued1 yr1/10/1−98%
Cobo et al. (2006)375 mg/m2 once weekly × 4ARB18 mo1/10/1−97%
Gallon and Chhabra (2006)375 mg/m2 once weekly × 4ACE-I and maintenance immunosuppression2 yr1/10/1−97%
Ruggenenti et al. (2006)b375 mg/m2 once weekly × 4ACE-I titrated to maximum tolerated dose, with ARB added after 3 mo12 mo6/23 (proteinuria <1 g/24h)6/23 (proteinuria <3 g/24h)−71%
Cravedi et al. (2007)375 mg/m2 × 1 (n = 11), 375 mg/m2 × 2 (n = 1)ACE-I titrated to maximum tolerated dose12 mo2/12 (proteinuria <0.3 g/24h)6/12 (proteinuria <3 g/24h with a >50% reduction from baseline)−60%
Fervenza et al. (2008)1 g × 2, on days 1 and 15; repeated at 6 mo if proteinuria >3 g/24h and CD19+ B cells >15/μl (n = 10)ACE-I + ARB12 mo2/15 (proteinuria <0.3 g/24h)6/15 (proteinuria <3 g/24h with a >50% reduction from baseline)−48%
Weclawiak et al. (2008)375 mg/m2 once weekly × 4, then 375 mg/m2 every 3 mo × 4ACE-I, ARB, and maintenance immunosuppression42 mo1/10/1−99%
Ruggenenti et al. (2008)c375 mg/m2 once weekly × 4ACE-I titrated to maximum tolerated dose7 to 59 mo7/7c0/7−95%
  • a The study reported the long-term (12 mo) follow-up of the 8 patients from the earlier Remuzzi et al. (2002) study.

  • b The study included 8 patients from the previous reports by Remuzzi et al. (2002) and Ruggenenti et al. (2003).

  • c The study reviews 50 consecutive patients with MN, treated with rituximab from May 2001 to January 2007, of whom 10 went into complete remission by 1 yr. The study only reports complete data for 7 patients with complete remission who agreed to undergo repeat biopsy. The 50 patients reported in this study include patients previously described in reports by Remuzzi et al. (2002), Ruggenenti et al. (2003, 2006), and Cravedi et al. (2007).